63 results about "Cutaneous tissue" patented technology

A minimally-invasive fluid-cooled insertion sleeve assembly, with an attached balloon and distally-located penetrating tip, into which sleeve any of a group comprising a rigid rod, a microwave-radiator assembly and an ultrasonic-imaging transducer assembly may be inserted, constitutes a probe of the system. The sleeve assembly comprises spaced inner and outer plastic tubes with two fluid channels situated within the coaxial lumen between the inner and outer tubes. The fluid coolant input flows through the fluid channels into the balloon, thereby inflating the balloon, and then exits through that coaxial lumen. An alternative embodiment has no balloon. The method employs the probe for piercing sub-cutaneous tissue and then ablating deep-seated tumor tissue with microwave-radiation generated heat.

Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

A minimally-invasive fluid-cooled insertion sleeve assembly, with an attached balloon and distally-located penetrating tip, into which sleeve any of a group comprising a rigid rod, a microwave-radiator assembly and an ultrasonic-imaging transducer assembly may be inserted, constitutes a probe of the system. The sleeve assembly comprises spaced inner and outer plastic tubes with two fluid channels situated within the coaxial lumen between the inner and outer tubes. The fluid coolant input flows through the fluid channels into the balloon, thereby inflating the balloon, and then exits through that coaxial lumen. An alternative embodiment has no balloon. The method employs the probe for piercing sub-cutaneous tissue and then ablating deep-seated tumor tissue with microwave-radiation generated heat.

Performing selective photothermolysis of sub-cutaneous tissue by using a plurality of beams of narrow band electro-magnetic radiation, where each of the beams have energy that is insufficient to heat the tissue that they strike to a temperature high enough to destroy such tissue, but by directing the individual beams to overlap at the target sufficient heat is generated to destroy the target tissue.

A phantom for prostate cancer brachytherapy has a prostate tissue phantom shaped like a real prostate gland, a perineal tissue phantom surrounding the prostate tissue phantom, a skin tissue phantom separating the perineal tissue phantom from an outside environment, and an enclosure. The prostate tissue phantom is a polyvinyl alcohol cryogel (PVA-C) having undergone 3-5 freeze-thaw cycles and having 10-20% w / w PVA in a solvent (e.g. water), 4-8% w / w oil and an amount of acoustic scattering particles to ultrasonically distinguish the prostate-tissue phantom from its surroundings. The perineal tissue phantom is a PVA-C having undergone 1-2 freeze-thaw cycles and having 10-20% w / w PVA in a solvent, 4-8% w / w oil and an amount of acoustic scattering particles to ultrasonically distinguish the perineal tissue phantom from its surroundings. The skin tissue phantom is a PVA-C having undergone at least 6 freeze-thaw cycles and having 15-25% w / w PVA in a solvent. The phantom mimics the imaging and mechanical properties of the prostate and surrounding tissues, providing a realistic phantom for prostate cancer brachytherapy.

Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

Apparatus is described for creating a direct mechanical connection between skeletal bone and a prosthetic device located outside of the body. The apparatus provides a means for creating an effective biologic seal to prevent the transmission of microbiologic particles into the body.

The invention discloses a skin model and application. The method comprises separately culturing epidermal cells and dermal cells derived from fetus scalp, newborn prepuce or adult scalp, and subculturing, wherein the used culture medium and culture method can maintain multiple functions of skin cells; separately digesting the cultured and proliferated multifunctional epidermal cells and dermal cells into single cells, and mixing to obtain suspension; transferring onto a semipermeable polymer or silica gel membrane substrate for incubation; transplanting cells on adhesive film to a receptor. The method can regenerate human intact functional skin and hair, the regenerated skin contains an epidermal layer, a dermal layer and a subcutaneous tissue as well as skin appendant organs. The skin model regenerated by the method disclosed by the invention can be used for study of human skin diseases, screening of skin drugs, and development of cell products for treating wound and other skin diseases.

A method and an apparatus for measuring glucose level in the body fluid of a subject, typically blood glucose level, by measuring impedance of a body tissue, with two pairs of electrodes, two electrodes for injecting current into a body tissue and two electrodes for detecting the ensuing voltage of the body tissue. The body tissue is typically a sub-dermal or sub-cutaneous tissue. The measured impedance of the body tissue is used to correlate with directly determined glucose levels to determine the glucose level from the measured impedance. It is thus possible to determine body fluid glucose levels in a reliable and reproducible manner.

The invention relates to a device for carrying out the nondestructive optical constant imaging of a human body cutis pathologic tissue and a method thereof. The device comprises a tungsten halogen lamp, an incident fiber optic probe, a line array CCD for receiving diffused reflection light, and a grating spectrograph, an amplification filter circuit, an A / D conversion circuit, a computer and a computer-controlled three-dimensional traveling table which are connected in turn through an optical fiber. The invention uses the line array CCD optical measurement device detecting the obliquely incident diffused reflection light to detect the human body cutis tissue, uses a Monte Carlo statistical method limited by characteristic parameters to conversely compute the values of the absorption coefficient and the reduction scattering coefficient at each two-dimensional space coordinates of the detected cutis tissue, then uses the grating spectrograph to carry out spectrum, and respectively images through the absorption coefficient and the reduction scattering coefficient and simultaneously detects the detected human body pathologic tissue and a healthful tissue around the pathologic tissue. Then the optical constants of the pathologic tissue and the healthful tissue are compared to see difference or the optical constant of the pathologic tissue is compared with a healthful human body tissue sample, thereby carrying out the diagnosis and identification of diseases.

Metering systems and methods are disclosed. A metering system is part of a larger fluidics sub-system that includes a flexible reservoir for storing insulin and a cannula assembly for delivering the insulin into sub-cutaneous tissue. The metering system draws a small dose of fluid from the reservoir and then pushes it down the cannula line and into the patient. The fluid dose is small relative to the reservoir volume, such that many pump strokes are required to completely empty the reservoir.

The invention relates to the use of a Rhodiola crenulata extract, via the topical route, for increasing the energy metabolism of the cutaneous tissues of a subject. The invention relates notably to topical compositions which comprise an active agent for increasing the energy metabolism of the cutaneous tissues of a subject, said active agent being a Rhodiola crenulata extract. The present invention enables making a cosmetic care such as fighting against, or slowing down or preventing the loosening of the cutaneous tissue, increasing the plasticity of the cutaneous tissue, exerting an anti-wrinkle effect or slowing down or preventing the appearance of wrinkles, fighting against, slowing down or preventing the appearance of acne, exerting a depigmenting effect of the cutaneous tissue, in particular of the skin, and promoting desquamation of the cutaneous tissue (or “peeling”).

The present invention relates to a microscopic-spots irradiating device applying a vacuum thereof that is provided with a laser beam or flash-lamp light-generating device, a multiple microscopic-spot generating device that creates multiple microscopic spots in cutaneous tissues, and a suction device that sucks up cutaneous tissues during the illumination thereof by the laser beam or flash lamp. The irradiating device of the present invention performs a laser treatment by forming a large number of microscopic spots in subcutaneous tissues that have been pulled up and stretched by suction, making it possible to encourage the treatment of pigmented lesions and regenerate new skin, while minimizing post-inflammatory or post-operative hyperpigmentation.

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and non-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, duration and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.

The present invention is a method for cutting a fowl to create a meat cut which includes the radius bone and muscles (meat) adhering to the radius bone. The method involves separating the radius bone and muscles adhering to the radius bone from the carcass of the fowl, and then removing the radius bone and muscles adhering to the radius bone from the carcass of the fowl. The meat cut may be produced with the cutaneous tissues attached to the muscles adhering to the radius bone or with the cutaneous tissues removed from the muscles adhering to the radius bone to produce a skinless meat cut. The resulting meat cut contains a larger percentage of meat and is easier to consume. Alternatively, a portion of the muscles (meat) adhering to the radius bone can be removed to create a meat cut having less meat.

The invention discloses a short interfering ribonucleic acid (siRNA) molecule for promoting scarless healing of skin wounds, a cocktail combination of a plurality of siRNA molecules targeting a plurality of related genes of scarless healing of wounds, and a pharmaceutical composition taking the siRNA molecule or the cocktail combination thereof as an active ingredient. Proven by cell experiments and mouse and pig skin wound models, the pharmaceutical composition can promote scarless healing of skin wounds resulted from traumata, surgical operation, or diabetes skin ulcer and the like, wherein the siRNA molecule can target genes causing pathological repair of wounds or adverse reactions; the siRNA double chains have different lengths and different tail ends and can target a homologous sequence of the same gene of cells of human, mouse and pig; the plurality of siRNAs in the cocktail combination can simultaneously inhibit various related genes of wound inflammation and revascularization, and has more obvious drug effects; and pharmaceutical carriers such as histidine-lysine polymer, dendritic polymer or liposome and the like in the pharmaceutical composition in a nanoparticle form can enhance the siRNA to be introduced into the skin tissue.

Compositions, formulations, methods, and systems for treating regional fat deposits and fat-related conditions, dermal conditions, and muscular conditions. Methods comprise administering a composition comprising at least one compound that reduces desensitization of beta adrenergic receptors, for example a glucocorticosteroid, and / or at least one long-acting beta-2 adrenergic receptor agonist, for example, formoterol. Compositions to be administered include sustained release formulations comprising at least one long-acting beta-2 adrenergic receptor agonist, at least one compound that reduces desensitization of beta adrenergic receptors, or both in a sustained crystalline microparticle form.

Pharmacological test shows that the externally-used preparation of Cetirizine has ideal allergy resistant and anti-inflammatory action to the rat passive cutaneous anaphylaxis (Rat PCA) model and dimethylbenzene caused mouse otitis model, and also prevents the adverse effect to the central system caused by whole body administration. It is also found in the test, that the externally used preparation of Cetirizine also has very fine inhibitory action to dinitrofluorobenzene caused mouse porphyria hypersensitivity (PTH), the novel pharmacological action of the Cetirizine shows that the Cetirizine external preparation has good therapeutic action to skin inflammations which mainly include porphyria hypersensitivity.

The present invention includes a growth factor profile, connective tissue matrix constituents, and immunoprivileged status of equine placental tissue extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render equine placental tissue an ideal source for biological scaffolds for xenotransplantation, and optionally adding at least one of: one or more block-copolymers, one or more osteogenic agent or one or more osteoinductive agents.

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and non-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, duration and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.

The present invention identifies genes whose gene products are differentially expressed lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema.

The invention belongs to the field of biomedical polymer materials, and discloses a micro-needle array patch capable of generating gas to take effect quickly and preparation and application thereof. The micro-needle array patch comprises a substrate and a needle tip located on the substrate, the substrate is composed of a biocompatible matrix, the needle tip is mainly composed of the biocompatible matrix and inorganic particles capable of generating gas, and the inorganic particles capable of generating gas are formed on the surface and / or in the biocompatible matrix of the needle tip; the needle tip part of the micro-needle array patch can interact with skin tissue fluid to generate gas during application, rapid dissolution of micro-needles and diffusion of drugs to a corium layer are promoted, and the drugs can be efficiently and rapidly delivered to subcutaneous parts and take effect without the help of external equipment.

The present invention identifies genes whose gene products are differentially expressed in lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema.

The invention discloses a human skin tissue endogenous polypeptide PDHPS1 and an application thereof. The amino acid sequence of the human skin tissue endogenous polypeptide PDHPS1 is shown in SEQ IDNO.1. The polypeptide PDHPS1 inhibits the propagation of a scar dermal fibroblast, inhibits the expression of mRNA of collagen genes COL1A1 and COL1A2 in the scar dermal fibroblast, and obviously reduces the protein expression of a main marker alpha-SMA of a myofibroblast in the scar dermal fibroblast. The human skin tissue endogenous polypeptide PDHPS1 can be used to prepare a drug or agent whichcan inhibit the propagation of the scar dermal fibroblast, reduce the collagen content and reduce the amount of the myofibroblast, and provides a new target spot for inhibiting the scar hypertrophy.

Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

An agent for preventing or improving wrinkles which comprises a substance inhibiting the activity of ADAM (a disintegrin and metalloprotease) contained in the skin. Wrinkles are prevented or improved by applying the substance, which inhibits the activity of ADAM contained in the skin, to the skin. An anti-wrinkle effect of a test substance is evaluated by using as an indication the enzymatic activity of ADAM or a gene expression level thereof in the skin, a tissue or a cell.

The invention discloses a functional gel layer, a scar patch and a preparation method of the scar patch, and relates to the technical field of medical supplies. The functional gel layer comprises the following components in parts by weight: 2-30 parts of a protein repairing agent, 0.5-10 parts of sodium hyaluronate and the balance of purified water, and the sum of the parts by weight of the components is 100; the protein repairing agent is selected from at least one of collagen and mussel mucin. The scar patch disclosed by the invention can be directly applied to non-closed wounds, and can be used for inhibiting scar formation, reducing the itching degree, promoting wound healing and accelerating functional recovery of skin tissues.